Your browser doesn't support javascript.
loading
Maintenance effect of a once-weekly regimen of a Selenium Disulfide-based shampoo in moderate-to-severe scalp seborrheic dermatitis after initial treatment with topical corticosteroid/salicylic acid.
Massiot, Philippe; Reygagne, Pascal; Chagnoleau, Corinne; Kanoun-Copy, Leila; Pouradier, Florence; Loussouarn, Geneviève; Queille-Roussel, Catherine; Jouni, Hussein; Kerob, Delphine.
Afiliação
  • Massiot P; L'Oréal Research and Innovation, Saint-Ouen, France.
  • Reygagne P; Centre Sabouraud, Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
  • Chagnoleau C; L'Oréal Research and Innovation, Saint-Ouen, France.
  • Kanoun-Copy L; L'Oréal Research and Innovation, Saint-Ouen, France.
  • Pouradier F; L'Oréal Research and Innovation, Saint-Ouen, France.
  • Loussouarn G; L'Oréal Research and Innovation, Saint-Ouen, France.
  • Queille-Roussel C; CPCAD, Hôpital l'Archet Nice, France.
  • Jouni H; L'Oréal Research and Innovation, Aulnay-sous-Bois, France.
  • Kerob D; Cosmetic Active International, Levallois-Perret, France.
Eur J Dermatol ; 33(S1): 13-18, 2023 Mar 01.
Article em En | MEDLINE | ID: mdl-37098774
INTRODUCTION: Seborrheic dermatitis (SD) is a chronic, relapsing, inflammatory disorder of the head and trunk. OBJECTIVES: To explore the potential of a 1% Selenium disulphide (SeS2)-based shampoo to prevent relapses of scalp SD (SSD) following corticosteroid/salicylic acid (TCS/SA) treatment. MATERIALS & METHODS: After a 2-week treatment with TCS/SA, adult patients with moderate-to-severe SSD received either the SeS2-based shampoo or its vehicle for eight weeks in a randomized, double-blinded fashion. Visits took place at baseline, weeks 2, 6 and 10. SSD severity was assessed based on erythema, flakes and pruritus; patients assessed the severity of pruritus. Global investigator and patient satisfaction were assessed at week 10. RESULTS: Forty-eight adults were included. After four and eight weeks of post TCS/SA maintenance regimen, 8.1% and 16.7% in the SeS2, and 41.7% and 54.2% in the vehicle group relapsed, respectively. First median time-to-relapse in the vehicle group was 56 days; this was not reached for SeS2. After two weeks of TCS/SA, the prevalence of patients with no pruritus was 29.2% in the SeS2 group, and 41.7% in the vehicle group; it increased to 76.2% with SeS2 and to 57.1% with the vehicle at the end of the study. The clinical benefit of treatment with TCS/SCA was maintained in the SeS2 group only. Investigators and patients were highly satisfied with the efficacy of SeS2. Tolerance to SeS2 was excellent, with no reported adverse events. CONCLUSION: The SeS2-based shampoo significantly reduces the time-to-relapse of moderate-to-severe SSD flares. Its tolerance was excellent, with no reported adverse events.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dermatoses do Couro Cabeludo / Dermatite Seborreica / Caspa Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Eur J Dermatol Assunto da revista: DERMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dermatoses do Couro Cabeludo / Dermatite Seborreica / Caspa Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Eur J Dermatol Assunto da revista: DERMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França